# Tandem Diabetes Care Inc. Tandem Diabetes Care Inc. is an other based in San Diego, United States. ## Overview - **Organization type:** other - **Headquarters:** San Diego, United States - **Region:** North America - **Address:** San Diego, CA, United States - **Assets under management:** Undisclosed - **Website:** tandemdiabetes.com ## Regulatory record - **Reports private funds:** No ## About Tandem Diabetes Care develops insulin pumps & other products and services that bring innovation, convenience & style to diabetes management. Explore Tandem’s insulin delivery systems today. ## Sectors - Digital Health - Healthcare Services ## Questions ### Who leads product development at Tandem Diabetes Care? Tandem's product development is overseen by its executive team under CEO John Sheridan (as of 2025, the CEO is John Sheridan, per the company's 2024 proxy statement). The R&D team includes engineers focused on hardware, embedded software, and algorithm design. The company does not publicly name a single chief medical officer or head of product. ### How does Tandem's Control-IQ+ technology differ from Medtronic's SmartGuard? Control-IQ+ uses a model-predictive control algorithm that adjusts basal insulin every five minutes based on CGM trends and also delivers automatic correction boluses when glucose is predicted to exceed 180 mg/dL. Medtronic's SmartGuard uses a simpler threshold-suspend approach. Clinical data from a 2023 study showed Tandem's system improved time-in-range by about 2.6 hours per day compared to a control group (per Beck RW et al., Diabetes Technology & Therapeutics, 2023). ### What is Tandem's distribution model outside the United States? Tandem sells directly in the US and through distributors in select international markets, including Canada, the UK, Germany, and Australia (per company 2023 Annual Report). The company also operates a subsidiary in Germany. It does not disclose distributor names or country-level revenue. ### Has Tandem issued recalls or safety warnings for its pumps? Yes. In 2022, Tandem issued an urgent medical device correction for the t:slim X2 regarding a potential occlusion alarm issue. In 2024, the FDA issued a Class I recall for certain Tandem Mobi pump charging cables due to fire risk (per FDA recall database, January 2024). No deaths were associated with either event. ### Who are Tandem's primary competitors? Tandem competes with Medtronic (MiniMed series), Insulet (Omnipod), and Roche (Accu-Chek) in the insulin pump market. It also faces competition from emerging startups such as EOFlow (now under Medtronic) and Beta Bionics (iLet pump). In the CGM space, Tandem partners with Dexcom and Abbott rather than competing. ### What is the revenue mix between hardware and consumables for Tandem? Tandem does not separately break out hardware versus consumables revenue in its financial filings. However, the company's 2023 10-K notes that pump shipments generate upfront revenue and recurring revenue from infusion sets, reservoirs, and CGM sensors sold through its channel. The majority of revenue in 2023 came from pump sales and supplies combined ($748M total revenue). ## Related profiles - [JLC Family Office](https://altss.com/profile/jlc-family-office) - [Berlin Packaging L.L.C.](https://altss.com/profile/berlin-packaging-llc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/tandem-diabetes-care-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology